RESUMEN
OBJECTIVE: Recurrent fetal loss, defined as the occurrence of three or more consecutive spontaneous abortions regardless of previous live birth, is a condition that affects about 2% of all reproductive-aged women. The role of gene mutations in recurrent pregnancy loss is not fully understood. The present research examined the relationship between factor V Leiden, factor V HR2, prothrombin G20210A and MTHFR and recurrent fetal loss in a case-control study. METHODS: Women aged 22-45 with a history of three or more fetal losses, being seen at a perinatal medicine clinic in New Jersey or Georgia, were eligible as cases. Overall, the study consisted of 60 women with three or more fetal losses and 92 women with at least one successful pregnancy. RESULTS: Factor V HR2 and MTHFR were not related to recurrent fetal loss. The prothrombin G20210A mutation appeared to confer an elevation in risk but the association was based upon small numbers and was not statistically significant (OR 4.8, 95% CI 0.50-47.2). Cases were 90% less likely to have the factor V Leiden mutation than controls (OR 0.10, 95% CI 0.01-0.81). CONCLUSIONS: Our study did not demonstrate that women who are carriers of the factor V, prothrombin, or MTHFR mutations are at higher risk of recurrent fetal loss than women without these mutations. In regards to factor V Leiden, the prevalence in our cases (1.7%) was not statistically different from the known population prevalence of 5%. However, the high prevalence in our controls (14%) was unusual. Factor V Leiden may protect against bleeding in early pregnancy.
Asunto(s)
Aborto Habitual/genética , Factor V/genética , Mutación , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/genética , Protrombina/genética , Adulto , Estudios de Casos y Controles , Femenino , Predisposición Genética a la Enfermedad , Humanos , Modelos Logísticos , Persona de Mediana Edad , Oportunidad Relativa , Embarazo , Proteína C/genética , Proteína S/genética , Factores de RiesgoRESUMEN
Moderate hyperhomocysteinemia is a putative risk factor for cardiovascular disease. Molecular studies have demonstrated increased plasma homocysteine levels in the presence of DNA mutations in either the methylenetetrahydrofolate reductase (MTHFR) enzyme found in the remethylation pathway or the enzyme cystathione beta-synthase (CBS) of the transsulfuration pathway. To determine whether the mutation C-->T677 in the MTHFR gene or the T-->C833/844ins68 and G-->A919 mutations in the CBS gene are associated with myocardial infarction (MI) in African Americans, DNA was analyzed from samples obtained from a case-control study conducted at a large, inner-city hospital. One-hundred ten African American subjects with a diagnosis of MI and 185 race- and age-matched controls were recruited. Our results demonstrated that 15% of the MI cases were heterozygous for the C-->T677 (MTHFR) mutation, while 1.8% were homozygous. When compared to the controls in which 15% were heterozygous and 2.1% were homozygous, no significant association with MI was observed. In addition, 34% of the cases were heterozygous for the T-->C833 (CBS) mutation while 6% were homozygous. This is compared to 32% and 5% of the controls having the heterozygous and homozygous genotype, respectively. No significant association was observed for the T-->C833 (CBS) mutation among the cases and controls. Although this mutation has no significant association with MI, the prevalence of the heterozygous state was higher than what has been reported for whites (12%). No mutations for G-->A919 (CBS) were detected in the cases or controls. The racial differences of the CBS T-->C833 polymorphism suggest that further investigation into the other areas of the CBS gene is needed.
Asunto(s)
Sustitución de Aminoácidos , Negro o Afroamericano , Cistationina betasintasa/genética , Hiperhomocisteinemia/genética , Mutación Missense , Infarto del Miocardio/genética , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/genética , Adulto , Población Negra/genética , Estudios de Casos y Controles , Comorbilidad , Cistationina betasintasa/biosíntesis , Análisis Mutacional de ADN , Inducción Enzimática , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Georgia/epidemiología , Humanos , Hiperhomocisteinemia/complicaciones , Hiperhomocisteinemia/enzimología , Hiperhomocisteinemia/etnología , Hipertensión/epidemiología , Masculino , Metilenotetrahidrofolato Reductasa (NADPH2) , Persona de Mediana Edad , Infarto del Miocardio/enzimología , Infarto del Miocardio/etnología , Infarto del Miocardio/etiología , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/biosíntesisRESUMEN
OBJECTIVES: It has been hypothesized that Legg-Perthes disease is caused by repeated vascular interruptions of the blood supply to the proximal femur, which are precipitated by coagulation system abnormalities. To test this theory, we conducted a case-control study among 57 patients with Legg-Perthes disease and an equal number of community controls. We measured protein C and protein S and resistance to activated protein C (APC-R) from plasma. STUDY DESIGN: Participants were placed into 1 of 3 mutually exclusive categories based on the control distribution: 1) normal, defined as either above or within 1 standard deviation below the expected mean; 2) low normal, defined as between 1 and 2 standard deviations below the expected mean; and 3) low, defined as >2 standard deviations below the expected mean. DNA was analyzed to determine the presence of a point mutation in the factor V gene that causes APC-R. RESULTS: We observed a statistically significant increased risk of Legg-Perthes disease with decreasing levels of protein C and a nearly significant increased risk with decreasing levels of protein S. The factor V gene defect was present in 5 (9%) of 55 cases and 3 (5%) of 56 controls (odds ratio 1.8, 95% confidence interval: 0.4-7.7), but the mean level on the APC-R plasma test was similar for cases and controls. Nine cases and 1 control had 2 low normal or low test results (odds ratio 13.0, 95% confidence interval: 2.2-75). CONCLUSIONS: Our results support the belief that abnormalities of the coagulation system leading to a thrombophilic state play a role in Legg-Perthes disease; however, larger studies are needed before definitive recommendations for coagulation testing can be made.
Asunto(s)
Enfermedad de Legg-Calve-Perthes/sangre , Proteína C/análisis , Proteína S/análisis , Resistencia a la Proteína C Activada/fisiopatología , Adolescente , Adulto , Pruebas de Coagulación Sanguínea , Niño , Preescolar , Factor V/genética , Femenino , Humanos , Enfermedad de Legg-Calve-Perthes/genética , Enfermedad de Legg-Calve-Perthes/fisiopatología , Masculino , Mutación Puntual/genética , Proteína C/fisiología , Proteína S/fisiología , Factores de RiesgoRESUMEN
AIM: To describe 21 cases of symptomatic rickets in adolescents. METHODS: The setting was a primary and secondary care hospital in Saudi Arabia providing medical care to Saudi Arab company employees and their families. Cases of symptomatic rickets diagnosed between January 1996 and December 1997 in adolescents aged 10 to 15 years were assessed with respect to clinical presentation, biochemical and radiological evaluation, dietary assessment, and estimation of sun exposure. RESULTS: Symptomatic rickets developed in 21 adolescents (20 females), with a prevalence rate of 68 per 100 000 children years. Presentation included carpopedal spasms (n = 12), diffuse limb pains (n = 6), lower limbs deformities (n = 2), and generalised weakness (n = 1). Biochemical findings included hypocalcaemia (n = 19), hypophosphoraemia (n = 9), raised serum alkaline phosphatase (n = 21) and parathormone (n = 7), and reduced 25-hydroxyvitamin D concentrations (n = 7). Radiological studies were suggestive of rickets in only eight children. All children had an inadequate dietary calcium and vitamin D intake. All but one had less than 60 minutes sun exposure per day. CONCLUSION: Even in sunny climates, adolescents, especially females, can be at risk of rickets. Hypocalcaemic tetany and limb pains were the most common presenting symptoms. Radiological evidence was not present in every case.
Asunto(s)
Raquitismo/diagnóstico , 25-Hidroxivitamina D 2/sangre , Adolescente , Fosfatasa Alcalina/sangre , Calcio de la Dieta/administración & dosificación , Niño , Registros de Dieta , Femenino , Crecimiento , Humanos , Hipocalcemia/complicaciones , Masculino , Política Nutricional , Dolor/etiología , Fósforo/sangre , Raquitismo/etiología , Raquitismo/metabolismo , Arabia Saudita , Luz Solar , Tetania/etiología , Vitamina D/administración & dosificaciónRESUMEN
OBJECTIVE: Description of rickets as an unexpected initial manifestation in two children with abetalipoproteinemia and hypobetalipoproteinemia, and elucidation of its pathophysiology in these conditions. METHODOLOGY: Two infants aged two and six months with abetalipoproteinemia and hypobetalipoproteinemia respectively had clinical rickets at presentation, confirmed radiologically and biochemically. Vitamin D intake and serum levels were measured and other causes of rickets were looked for. RESULTS: Vitamin D intake and laboratory studies levels were suggestive of rickets due to calcium deficiency instead of vitamin D deficiency. Healing of rickets occurred with dietary treatment of the malabsorption, without any dietary calcium or significant vitamin D supplementation. CONCLUSION: Steatorrhea-induced calcium malabsorption seems to be the most likely cause of rickets in this entity.
Asunto(s)
Abetalipoproteinemia/complicaciones , Hipobetalipoproteinemias/complicaciones , Raquitismo/complicaciones , Abetalipoproteinemia/metabolismo , Calcio/metabolismo , Femenino , Humanos , Hipobetalipoproteinemias/metabolismo , Lactante , Síndromes de Malabsorción/complicaciones , Síndromes de Malabsorción/metabolismo , Masculino , Raquitismo/etiología , Raquitismo/metabolismoAsunto(s)
Polimorfismo Genético , Complicaciones Hematológicas del Embarazo/sangre , Activador de Tejido Plasminógeno/genética , Trombosis de la Vena/sangre , Alelos , Elementos Alu , Población Negra/genética , Estudios de Casos y Controles , Femenino , Fibrinolíticos/sangre , Frecuencia de los Genes , Humanos , Embarazo , Complicaciones Hematológicas del Embarazo/epidemiología , Tromboembolia/sangre , Tromboembolia/epidemiología , Tromboembolia/genética , Activador de Tejido Plasminógeno/sangre , Trombosis de la Vena/epidemiología , Trombosis de la Vena/genética , Población Blanca/genéticaRESUMEN
Thrombophilia is a multigenic disease in which the combination of genetic polymorphisms increases the risk of deep vein thrombosis (DVT). The rapid identification of these genetic combinations requires high-throughput analysis of single nucleotide polymorphisms (SNPs). The TaqMan fluorogenic 5'-->*3' nuclease assay (PE/Applied Biosystems, Foster City, CA) with custom-designed primers, probes and controls has provided a highly efficient platform for high throughput. This assay was used to rapidly detect two SNPs, FV Leiden (G1691A) and FV A4070G (R2 allele), in a study of 6295 subjects. With one thermal cycler, we completed sample set-up, PCR and analysis on 84 samples in 3 h with an additional 12 wells containing 4 "no template controls" (NTC), 4 "allele-1 controls", and 4 "allele-2 controls" in a 96-well plate. When additional thermal cyclers were used and more assays were set up while the initial sets of reactions were in the PCR machines, the output could correspondingly be increased. The TaqMan assay was extremely accurate, avoided contamination by using uracil-N-glycolase (UNG) in a single, closed tube, and offered the possibility for additional automation with robotic equipment to implement the PCR. This TaqMan assay facilitates high throughput to screen large populations quickly and economically while utilizing a simple protocol that requires minimal expenditure of personnel time. Our results demonstrated a prevalence of the R2 allele of 11.9% in U.S. Caucasians, 5.6% in African-Americans, 13.4% in Asian or Pacific Islanders and 11.3% in Hispanics. No association between venous thromboembolism and the R2 allele was noted, and furthermore no interaction with FV Leiden was observed.
Asunto(s)
Factor V/genética , Pruebas Genéticas/métodos , Polimorfismo de Nucleótido Simple , Trombosis de la Vena/genética , Alelos , California/epidemiología , Frecuencia de los Genes , Predisposición Genética a la Enfermedad/epidemiología , Haplotipos , Humanos , Reacción en Cadena de la Polimerasa/instrumentación , Reacción en Cadena de la Polimerasa/métodos , Prevalencia , Grupos Raciales/genética , Juego de Reactivos para Diagnóstico , Tromboembolia/epidemiología , Tromboembolia/genética , Trombosis de la Vena/epidemiologíaRESUMEN
OBJECTIVE: Polymorphisms in the genes for factor V (factor V Leiden), prothrombin, methylenetetrahydrofolate reductase, and angiotensin-converting enzyme have been associated with the occurrence of venous thrombosis. The objective of this study was to determine the relationships of these polymorphisms to thrombosis during pregnancy. STUDY DESIGN: This case-control study included 41 case patients with venous thrombosis during pregnancy and 76 control subjects matched for hospital and for race (white vs black) who had a normal pregnancy. RESULTS: Among white subjects, mutations in the genes for factor V and prothrombin were associated with increased risks of venous thrombosis during pregnancy (factor V: odds ratio, 18.3; 95% confidence interval, 2.7-432; P =.001; prothrombin: odds ratio infinity; 95% lower confidence limit, 1.7; P =.01). No black subject had either of these two mutations. For both black and white subjects the D/D genotype of the gene for angiotensin-converting enzyme entailed increased risk compared with the other genotypes (odds ratio, 2.7; 95% confidence interval, 1.2-6.3; P =.02). The polymorphism in the gene for methylenetetrahydrofolate reductase was unrelated to thrombosis during pregnancy among both blacks and whites. CONCLUSION: Women who had thrombotic complications during pregnancy demonstrated an increased prevalence of genetic mutations related to coagulation. The additional risk of thrombosis during pregnancy associated with such genetic mutations can be substantial.
Asunto(s)
Complicaciones Cardiovasculares del Embarazo , Trombosis de la Vena/genética , Población Negra/genética , Estudios de Casos y Controles , Factor V/genética , Femenino , Predisposición Genética a la Enfermedad/genética , Genotipo , Humanos , Metilenotetrahidrofolato Deshidrogenasa (NADP)/genética , Mutación/fisiología , Peptidil-Dipeptidasa A/genética , Embarazo , Protrombina/genética , Valores de Referencia , Estados Unidos , Población Blanca/genéticaRESUMEN
BACKGROUND: Porcine clotting factor has been used for more than 15 years to treat severe bleeding episodes in persons with hemophilia who have antibodies to human clotting factor. In 1996, QC procedures revealed for the first time the presence of porcine parvovirus (PPV) in the product. This report describes an investigation to determine the extent of product contamination and to evaluate past recipients of porcine clotting factor (Hyate:C, Speywood Biopharm) for evidence of PPV infection. STUDY DESIGN AND METHODS: Stored specimens from 22 lots of previously released Hyate:C were tested for the presence of PPV DNA by PCR and nested PCR assays. Serum specimens from 98 recipients of Hyate:C and 24 controls who did not receive Hyate:C were tested for PPV antibodies by an immunofluorescence assay. RESULTS: PPV DNA was detected in product from 21 of the 22 lots of Hyate:C, primarily by nested PCR testing. In contrast, none of the serum specimens from the 98 Hyate:C recipients tested positive for PPV IgG antibodies. CONCLUSION: The risk of human disease from percutaneous exposure to low levels of PPV seems to be low. Nevertheless, the theoretical risk of human infection with PPV has led to manufacturing changes, including PCR screening of all porcine plasma, which are designed to eliminate this risk.
Asunto(s)
Anticuerpos Antivirales/sangre , ADN Viral/sangre , Contaminación de Medicamentos , Factor VIII/efectos adversos , Hemofilia A/complicaciones , Infecciones por Parvoviridae/veterinaria , Parvoviridae/aislamiento & purificación , Enfermedades de los Porcinos/transmisión , Porcinos/virología , Adulto , Animales , Canadá/epidemiología , Hemofilia A/terapia , Humanos , Masculino , Parvoviridae/genética , Parvoviridae/inmunología , Infecciones por Parvoviridae/epidemiología , Infecciones por Parvoviridae/transmisión , Reacción en Cadena de la Polimerasa , Estudios Retrospectivos , Estudios Seroepidemiológicos , Método Simple Ciego , Porcinos/sangre , Estados Unidos/epidemiología , Viremia/veterinaria , ZoonosisRESUMEN
A genetic variation in the prothrombin gene is located in the 3-untranslated region at position 20210 where a G-->A transition occurs. The prevalence of the mutation is 1% to 2% in white populations, and the mutation is associated with an increased risk of venous thrombosis and myocardial infarction. We report the prevalence of the A allele in blacks at birth; in black control subjects with no history of heart attack, stroke, or blood clots; in black patients with venous thrombosis; and in black patients with myocardial infarction. Among 318 infants, the prevalence of the A allele was 0.2% (1 heterozygote), with an exact, one-sided upper 95% confidence limit of 0.7%. Among 185 control subjects the variant was absent, yielding an exact, one-sided upper 95% confidence limit of 0.8% for the A allele. The heterozygous genotype was found in 2 of 91 subjects with deep vein thrombosis and in none of 123 subjects with myocardial infarction. The very low prevalence of the A allele indicates that the prothrombin variant is not a major cause of venous thrombosis or myocardial infarction in blacks.